Avantor Stock Price, News & Analysis

Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, has announced its plans to release its third quarter 2024 financial results on Friday, October 25, 2024. The company will release the results before the market opens and will hold a conference call on the same day at 8:00 a.m. Eastern Time to discuss the results.

Interested parties can access a live audio webcast of the session by visiting the Events & Presentations section in the Investor area of Avantor's website at ir.avantorsciences.com. For those unable to attend the live session, a replay of the webcast will be available for 30 days following the event.

Avantor (NYSE: AVTR) has entered into a 10-year virtual power purchase agreement through the Energize program, aimed at increasing renewable energy access for pharmaceutical supply chains. This agreement will provide 25GWh of renewable energy annually starting in 2026, reducing Avantor's greenhouse gas emissions by 17,465 metric tons, equivalent to the energy consumption of 2,278 households for one year. Avantor is also developing three new solar projects in Spain to support its European operations. Additionally, the company has completed solar installations in Singapore, India, Sweden, and New York, with more planned in New Jersey and other locations to meet its 2030 emissions reduction targets.

Avantor, Inc. (NYSE: AVTR) announced its participation in the BioProcess International 2024 conference, scheduled for September 23-26 in Boston. The company will deliver multiple scientific presentations and exhibit at the event, which is expected to attract over 3,200 biopharmaceutical professionals from 40+ countries.

Key presentations include:

• A novel approach to AAV harvest and purification process optimization
• Keynote address on adapting to changing molecules and regulatory expectations
• Viral gene therapy manufacturing at scale

Avantor will also showcase its Magnetic Mixing Systems portfolio on the exhibit floor, focusing on solutions for production scale-up and downstream process optimization. The company's presence at the conference underscores its commitment to delivering innovative solutions for biopharmaceutical development and production challenges.

Avantor (NYSE: AVTR), a leading global provider in life sciences and advanced technologies, has been awarded a Bronze Medal from EcoVadis for the second consecutive year. The company's sustainability performance score of 65, awarded in August 2024, places it in the top 17% of over 130,000 companies rated globally. This represents a significant 15-point improvement from its 2023 score.

Avantor's 'Science for Goodness' sustainability platform focuses on four pillars: People & Culture, Innovation & Environment, Community Engagement, and Governance & Integrity. This framework aims to create long-term value for all stakeholders, including associates, customers, suppliers, stockholders, and communities.

The EcoVadis rating, based on international sustainability standards, validates Avantor's commitment to sustainability and provides an actionable roadmap for continuous improvement in areas such as Environment, Labor and Human Rights, Ethics, and Sustainable Procurement.

Avantor, Inc. (NYSE: AVTR), a global leader in providing important products and services to life sciences and advanced technology industries, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The event will take place in New York on September 5, 2024.

Michael Stubblefield, President and CEO of Avantor, will engage in a fireside chat at approximately 10:45 a.m. Eastern Daylight Time. Interested parties can access a live audio webcast of the session through the Events & Presentations section of Avantor's investor relations website. The webcast replay will remain available for 30 days following the event.

Audax Private Equity has announced a definitive agreement to acquire Avantor's Clinical Services business (NYSE: AVTR). The deal is expected to close in Q4, subject to regulatory approvals. Clinical Services provides clinical trial and laboratory supply chain services to pharmaceutical and biotechnology companies, CROs, and diagnostic laboratories. Operating 10 facilities across the US, UK, and Europe, the business offers a global logistics and equipment services network.

The acquisition includes three primary offerings: EPL Archives, MESM, and Therapak, which provide active trial and post-trial sample storage, supply chain management, and packaging and logistics for sample collection. Audax plans to invest aggressively to expand the company's commercial and technical reach, leveraging its experience in corporate carveouts and the healthcare sector.

Avantor (NYSE: AVTR) has announced a definitive agreement to divest its clinical services business to Audax Private Equity for approximately $650 million. This strategic move aims to optimize Avantor's portfolio and sharpen its focus on lab and production businesses. The transaction, expected to close in Q4 2024, will generate about $475 million in after-tax cash proceeds, which will be used for debt paydown.

The divested business, part of Avantor's Laboratory Solutions segment, has around 800 employees and is projected to generate approximately $200 million in annual revenue for 2024. This divestiture aligns with Avantor's new operating model and is expected to strengthen the company's balance sheet while reducing interest expenses.

Avantor (NYSE: AVTR) reported its Q2 2024 financial results, showing a 2.4% decrease in net sales to $1.70 billion, with a 2.0% organic decline. The company's net income improved to $93 million from a loss in Q2 2023, while Adjusted EBITDA was $306 million with a 17.9% margin. Diluted GAAP EPS was $0.14, and adjusted EPS was $0.25. Avantor generated strong cash flow, with operating cash flow of $281 million and free cash flow of $235 million. The company reaffirmed its fiscal year 2024 guidance and reported sequential improvements in key financial metrics, including over 100 basis points of Adjusted EBITDA margin expansion.

Avantor announced the launch of two new products, J.T.Baker® Cell Lysis Solution and J.T.Baker® Endonuclease, aimed at optimizing the gene therapy harvest process. These products address biopharmaceutical demand for sustainable options while improving the efficiency and quality of viral particle harvests. The J.T.Baker® Cell Lysis Solution, a biodegradable alternative to Octoxynol-9, ensures low ecotoxicity and protects viral particles during processing. It also streamlines the harvest process by reducing contamination risks. In combination with J.T.Baker® Endonuclease, which removes residual impurities, these products offer scalable, efficient, and environmentally friendly solutions for gene therapy manufacturing.